See more : Country-Wide Insurance Company (CWID) Income Statement Analysis – Financial Results
Complete financial analysis of Amarin Corporation plc (AMRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amarin Corporation plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Keurig Dr Pepper Inc. (0Z62.L) Income Statement Analysis – Financial Results
- Y’s Table Corporation (2798.T) Income Statement Analysis – Financial Results
- Saudi Lime Industries Co. (9566.SR) Income Statement Analysis – Financial Results
- Enservco Corporation (ENSV) Income Statement Analysis – Financial Results
- Maral Overseas Limited (MARALOVER.NS) Income Statement Analysis – Financial Results
Amarin Corporation plc (AMRN)
About Amarin Corporation plc
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 306.91M | 369.19M | 583.19M | 614.06M | 429.76M | 229.21M | 181.10M | 130.08M | 81.76M | 54.20M | 26.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.37M | 500.00K | 500.00K | 1.02M | 7.37M | 65.51M | 53.77M | 17.55M | 11.22M | 19.00M | 24.30M | 21.50M | 29.10M | 18.70M | 14.70M |
| Cost of Revenue | 141.37M | 126.71M | 121.33M | 131.44M | 96.02M | 54.54M | 44.95M | 34.36M | 27.88M | 20.49M | 11.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 107.00K | 11.91M | 30.13M | 21.46M | 5.22M | 2.98M | 3.70M | 2.80M | 4.00M | 4.90M | 0.00 | 3.10M |
| Gross Profit | 165.54M | 242.48M | 461.86M | 482.62M | 333.74M | 174.67M | 136.15M | 95.72M | 53.88M | 33.72M | 14.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.37M | 500.00K | 500.00K | 910.00K | -4.55M | 35.38M | 32.32M | 12.33M | 8.24M | 15.30M | 21.50M | 17.50M | 24.20M | 18.70M | 11.60M |
| Gross Profit Ratio | 53.94% | 65.68% | 79.20% | 78.59% | 77.66% | 76.20% | 75.18% | 73.58% | 65.90% | 62.21% | 54.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 89.48% | -61.74% | 54.01% | 60.10% | 70.25% | 73.47% | 80.53% | 88.48% | 81.40% | 83.16% | 100.00% | 78.91% |
| Research & Development | 22.22M | 30.41M | 29.31M | 38.96M | 34.39M | 55.90M | 47.16M | 49.98M | 51.06M | 50.33M | 72.75M | 58.96M | 21.60M | 28.01M | 17.84M | 12.95M | 12.11M | 17.19M | 8.31M | 3.48M | 5.44M | 6.22M | 4.14M | 5.75M | 7.44M | 19.80M | 19.80M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 88.61M | 118.80M | 141.86M | 112.66M | 323.62M | 180.18M | 112.04M | 93.40M | 93.07M | 79.35M | 121.25M | 57.79M | 22.56M | 17.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 111.33M | 185.61M | 266.47M | 350.65M | 0.00 | 46.82M | 22.51M | 17.97M | 7.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 199.94M | 304.42M | 408.33M | 463.31M | 323.62M | 227.00M | 134.55M | 111.37M | 101.04M | 79.35M | 121.25M | 57.79M | 22.56M | 17.09M | 15.25M | 15.23M | 19.46M | 13.27M | 9.77M | 9.03M | 30.89M | 23.66M | 33.26M | 9.14M | 5.30M | 9.70M | 7.30M | 34.60M | 18.60M | 0.00 | 9.90M |
| Other Expenses | 10.97M | -740.00K | -302.00K | 104.00K | -75.00K | -326.00K | 74.00K | -482.00K | -228.00K | 3.73M | -1.19M | -427.00K | 0.00 | 0.00 | -2.16M | 0.00 | 9.17M | 674.00K | 676.00K | -510.00K | -2.05M | 39.24M | 0.00 | -1.00K | 2.32M | 2.60M | 2.50M | 1.20M | 1.00M | 0.00 | 600.00K |
| Operating Expenses | 233.13M | 334.83M | 437.64M | 502.27M | 358.02M | 282.90M | 181.71M | 161.35M | 152.10M | 129.67M | 194.00M | 116.75M | 44.16M | 45.10M | 30.93M | 28.18M | 40.73M | 31.13M | 18.76M | 12.00M | 34.27M | 69.12M | 37.40M | 14.89M | 15.05M | 32.10M | 29.60M | 35.80M | 19.60M | 0.00 | 10.50M |
| Cost & Expenses | 374.50M | 461.54M | 558.97M | 633.72M | 454.03M | 337.44M | 226.66M | 195.71M | 179.98M | 150.16M | 205.91M | 116.75M | 44.16M | 45.10M | 30.93M | 28.18M | 40.73M | 31.13M | 18.76M | 12.11M | 46.19M | 99.25M | 58.85M | 20.11M | 18.03M | 35.80M | 32.40M | 39.80M | 24.50M | 0.00 | 13.60M |
| Interest Income | 11.86M | 2.82M | 1.22M | 4.90M | 8.50M | 1.07M | 429.00K | 234.00K | 132.00K | 96.00K | 343.00K | 544.00K | 231.00K | 53.00K | 780.00K | 9.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.00K | 15.00K | 129.00K | 2.61M | 6.63M | 7.80M | 9.77M | 18.44M | 20.05M | 18.48M | 34.18M | 18.09M | 1.00K | 19.00K | 8.23M | 2.14M | 6.46M | 0.00 | 1.80M | 0.00 | 0.00 | 29.46M | 0.00 | 0.00 | 0.00 | 24.40M | 800.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.97M | 3.09M | 2.86M | 2.05M | 862.56K | 667.87K | 715.59K | 777.59K | 812.00K | 844.00K | 892.00K | 449.00K | 76.00K | 63.00K | 582.00K | 251.00K | 386.00K | 795.00K | 810.00K | 754.00K | 671.00K | 8.29M | 21.22M | 2.42M | 2.32M | 2.60M | 2.50M | 1.20M | 1.00M | 0.00 | 600.00K |
| EBITDA | -50.90M | -100.65M | 14.28M | -12.71M | -15.06M | -106.63M | -44.82M | -56.53M | -97.41M | -39.78M | -134.62M | -152.32M | -66.79M | -249.90M | -55.16M | -19.87M | -38.44M | -31.16M | -19.29M | -9.85M | -6.09M | -25.45M | 16.14M | -224.00K | -4.81M | -7.90M | -5.60M | -17.10M | 5.60M | 18.70M | 1.70M |
| EBITDA Ratio | -16.59% | -24.45% | 4.31% | -2.39% | -3.69% | -47.36% | -24.49% | -50.82% | -120.42% | -170.16% | -681.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -437.07% | -6,280.80% | -3,358.80% | -3,309.93% | -732.53% | 6.42% | 29.96% | -2.85% | -27.11% | -8.95% | -15.64% | -87.44% | 16.15% | 100.00% | 9.52% |
| Operating Income | -67.59M | -92.34M | 22.28M | -19.66M | -24.28M | -108.23M | -45.56M | -65.63M | -98.22M | -95.96M | -182.11M | -116.75M | -44.16M | -45.10M | -52.30M | -28.18M | -40.73M | -31.16M | -18.91M | -11.09M | -38.82M | -32.66M | -5.08M | -2.56M | -6.81M | -16.80M | -8.10M | -18.30M | 4.60M | 18.70M | 1.10M |
| Operating Income Ratio | -22.02% | -25.01% | 3.82% | -3.20% | -5.65% | -47.22% | -25.15% | -50.45% | -120.14% | -177.03% | -691.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -553.06% | -6,232.20% | -3,781.60% | -1,090.66% | -527.10% | -49.86% | -9.44% | -14.59% | -60.71% | -88.42% | -33.33% | -85.12% | 15.81% | 100.00% | 7.48% |
| Total Other Income/Expenses | 13.92M | 2.06M | 789.00K | 2.40M | 1.80M | -8.12M | -9.26M | -10.76M | -20.07M | 36.75M | 12.69M | -54.20M | -22.73M | -204.92M | -29.36M | 7.22M | -7.08M | 3.64M | -2.35M | 222.00K | 12.24M | -883.00K | -298.00K | 525.00K | -1.63M | -5.50M | -3.20M | 1.60M | 900.00K | 0.00 | 200.00K |
| Income Before Tax | -53.67M | -103.81M | 11.29M | -17.26M | -22.48M | -116.35M | -54.82M | -76.38M | -118.29M | -59.20M | -169.42M | -170.07M | -66.61M | -250.09M | -59.76M | -20.70M | -39.03M | -27.72M | -19.41M | 11.35M | -26.58M | -33.55M | -4.71M | -2.22M | -10.15M | -30.10M | -11.30M | -16.70M | 5.50M | 0.00 | 1.30M |
| Income Before Tax Ratio | -17.49% | -28.12% | 1.94% | -2.81% | -5.23% | -50.76% | -30.27% | -58.72% | -144.69% | -109.22% | -642.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -529.99% | -5,543.80% | -3,881.00% | 1,115.54% | -360.90% | -51.21% | -8.76% | -12.66% | -90.48% | -158.42% | -46.50% | -77.67% | 18.90% | 0.00% | 8.84% |
| Income Tax Expense | 5.44M | 2.00M | 3.56M | 745.00K | 164.00K | 96.00K | 13.05M | 9.97M | -3.09M | -2.84M | -3.19M | 9.12M | 2.52M | -501.00K | -440.00K | -674.00K | -837.00K | -799.00K | -698.00K | 7.33M | -7.36M | 3.54M | 412.00K | 342.00K | -27.00K | 100.00K | 600.00K | -1.10M | 1.40M | 15.90M | 500.00K |
| Net Income | -59.11M | -105.80M | 7.73M | -18.00M | -22.65M | -116.45M | -67.87M | -86.35M | -115.20M | -56.36M | -166.23M | -179.18M | -69.13M | -249.59M | -59.32M | -20.02M | -38.20M | -26.92M | -18.71M | 4.01M | -19.22M | -37.08M | -4.76M | 2.36M | 4.37M | -28.80M | -7.70M | -15.60M | 4.10M | 2.80M | 900.00K |
| Net Income Ratio | -19.26% | -28.66% | 1.33% | -2.93% | -5.27% | -50.80% | -37.47% | -66.38% | -140.91% | -103.99% | -630.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -518.63% | -5,384.00% | -3,741.40% | 394.49% | -261.02% | -56.61% | -8.85% | 13.43% | 38.96% | -151.58% | -31.69% | -72.56% | 14.09% | 14.97% | 6.12% |
| EPS | -0.15 | -0.26 | 0.02 | -0.05 | -0.07 | -0.39 | -0.25 | -0.41 | -0.64 | -0.32 | -1.03 | -1.24 | -0.53 | -2.49 | -1.40 | -0.91 | -4.08 | -3.35 | -4.63 | 1.72 | -11.24 | -39.71 | -0.67 | 6.42 | 2.90 | -19.29 | -52.00 | -110.00 | 31.00 | 20.00 | 8.00 |
| EPS Diluted | -0.15 | -0.26 | 0.02 | -0.05 | -0.07 | -0.39 | -0.25 | -0.41 | -0.64 | -0.32 | -0.99 | -1.24 | -0.53 | -2.49 | -1.40 | -0.91 | -4.08 | -3.35 | -4.63 | 1.72 | -11.24 | -39.71 | -0.40 | 3.02 | 2.90 | -19.29 | -52.00 | -110.00 | 31.00 | 20.00 | 8.00 |
| Weighted Avg Shares Out | 407.66M | 401.16M | 395.99M | 381.76M | 342.54M | 297.24M | 270.65M | 210.61M | 179.59M | 173.72M | 161.02M | 144.02M | 130.25M | 100.24M | 42.42M | 22.06M | 9.37M | 8.03M | 4.04M | 1.79M | 1.71M | 933.77K | 7.12M | 149.89K | 1.50M | 1.49M | 148.08K | 141.82K | 132.26K | 140.00K | 112.50K |
| Weighted Avg Shares Out (Dil) | 407.66M | 401.16M | 402.48M | 381.76M | 342.54M | 297.24M | 270.65M | 211.87M | 180.65M | 173.82M | 167.07M | 144.02M | 130.25M | 100.24M | 42.42M | 22.06M | 9.37M | 8.03M | 4.04M | 1.79M | 1.71M | 933.77K | 12.04M | 842.09K | 1.50M | 1.49M | 148.08K | 141.82K | 132.26K | 140.00K | 112.50K |
Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer
-- Provoost Brings More than 20 Years of Corporate Counsel Experience to Amarin -- DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Jonathan Provoost as the Company's new...
Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023
-- Additional Mechanistic Data on Eicosapentaenoic Acid (EPA) and Real-World Characteristics of Patients with Diabetes on IPE Also Featured at the Meeting -- -- Additional Mechanistic Data on Eicosapentaenoic Acid (EPA) and Real-World Characteristics of Patients with Diabetes on IPE...
Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin's senior management team to discuss the...
Amarin Corporation plc (AMRN) Cantor Fitzgerald Annual Global Healthcare Conference (Transcript)
Amarin Corporation plc (NASDAQ:AMRN ) Cantor Fitzgerald Annual Global Healthcare Conference September 26, 2023 9:55 AM ET CompanyParticipants Patrick Holt - President and CEO Conference Call Participants Carvey Leung - Cantor Fitzgerald Carvey Leung My name is Carvey Leung, and...
Amarin to Present at the 2023 Cantor Global Healthcare Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin's president and chief executive officer, is scheduled to participate via fireside chat at the 2023 Cantor Global Healthcare...
10 Top Penny Stocks To Buy According To Insiders In August
Engaging in the world of low-cost stocks often referred to as penny stocks, is appealing to those looking to capitalize on the potential upsides of the stock market. These stocks, priced below $5, are known for their intrinsic risk.
Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy
– Dutch Ministry of Health Approves VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce the Risk of Cardiovascular Events in Patients with Established Cardiovascular Disease –
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel
-- Agreement Follows Recent Regulatory Approval in Israel of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT –-
Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)
-- VAZKEPA® (icosapent ethyl) accepted by the Scottish Medicines Consortium (SMC) for restricted use within NHSScotland, as secondary prevention in adult statin-treated patients at high cardiovascular risk 1 -- -- VAZKEPA® already commercially available in England, Wales, and Northern Ireland...
Amarin (AMRN) Q2 Earnings and Revenues Surpass Estimates
Amarin's (AMRN) second-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.
Source: https://incomestatements.info
Category: Stock Reports